Synthesis and SAR of b-annulated 1,4-dihydropyridines define cardiomyogenic compounds as novel inhibitors of TGFβ signaling

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9946-9957

  Schade, Dennis ^a,b,c,d   Lanier, Marion ^a,c,e   Willems, Erik ^b,c   Okolotowicz, Karl ^a   Bushway, Paul ^b   Wahlquist, Christine ^b   Gilley, Cynthia ^a   Mercola, Mark ^b,c   Cashman, John R ^a,c  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

^b BURNHAM INSTITUTE   (United States)

^c ChemRegen Inc   (United States)

^d TU DORTMUND UNIVERSITY   (Germany)

^e Takeda San Diego Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; 4 (BIPHENYL 4 YL) 2,7,7 TRIMETHYL 5 OXO 1,4,5,6,7,8 HEXAHYDROQUINOLINE 3 CARBOXYLIC ACID; ACTIVIN A; ETHYL 4 (4 TERT BUTYLPHENYL) 2 METHYL 5 OXO 7 (N PROPYL) 1,4,5,6,7,8 HEXAHYDROQUINOLINE 3 CARBOXYLATE; ETHYL 4 (BIPHENYL 4 YL) 2,7,7 TRIMETHYL 5 OXO 1,4,5,6,7,8 HEXAHYDROQUINOLINE 3 CARBOXYLATE; ISOBUTYL 4 (4 TERT BUTYLPHENYL) 2 METHYL 5 OXO 7 (N PROPYL) 1,4,5,6,7,8 HEXAHYDROQUINOLINE 3 CARBOXYLATE; METHYL 2 (3 NITROBENZAMIDO) 3 (3 OXOBUTANOYLOXY)BUTANOATE; METHYL 4 (4 CYCLOHEXYLPHENYL) 2,7,7 TRIMETHYL 5 OXO 1,4,5,6,7,8 HEXAHYDROQUINOLINE 3 CARBOXYLATE; METHYL 4 (BIPHENYL 4 YL) 2 ETHYL 1,7,7 TRIMETHYL 5 OXO 1,4,5,6,7,8 HEXAHYDROQUINOLINE 3 CARBOXYLATE; METHYL 4 (BIPHENYL 4 YL) 2 ETHYL 7,7 DIMETHYL 5 OXO 5,6,7,8 TETRAHYDROQUINOLINE 3 CARBOXYLATE; METHYL 4 (BIPHENYL 4 YL) 2 METHYL 5 OXO 7 (N PROPYL) 1,4,5,6,7,8 HEXAHYDROQUINOLINE 3 CARBOXYLATE; METHYL 4 [3 (1H INDOL 5 YL)PHENYL] 2,7,7 TRIMETHYL 5 OXO 1,4,5,6,7,8 HEXAHYDROQUINOLINE 3 CARBOXYLATE; NIFEDIPINE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ANNULATION REACTION; ARTICLE; BIOLOGICAL ACTIVITY; CALCIUM SIGNALING; CHIRALITY; CONTROLLED STUDY; DRUG SYNTHESIS; EMBRYO; ENANTIOMER; HUMAN; HUMAN CELL; IC 50; PHARMACOPHORE; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ACTIVINS; ANIMALS; CALCIUM; CELL DIFFERENTIATION; CELLS, CULTURED; DIHYDROPYRIDINES; EMBRYONIC STEM CELLS; HUMANS; MICE; MOLECULAR STRUCTURE; MYOCYTES, CARDIAC; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; QUINOLONES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFORMING GROWTH FACTOR BETA;

EID: 84870050391     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301144g     Document Type: Article

References (30)

1. Willems, E.; Lanier, M.; Forte, E.; Lo, F.; Cashman, J.; Mercola, M. A chemical biology approach to myocardial regeneration J. Cardiovasc. Transl. Res. 2011, 4 (3) 340-350
2. Willems, E.; Bushway, P. J.; Mercola, M. Natural and synthetic regulators of embryonic stem cell cardiogenesis Pediatr. Cardiol. 2009, 30 (5) 635-642
3. Willems, E.; Teixeira, J. C.; Schade, D.; Cai, W.; Reeves, P.; Bushway, P. J.; Lanier, M.; Walsh, C.; Kirchhausen, T.; Izpizua Belmonte, J. C.; Cashman, J.; Mercola, M. Small molecule-mediated TGFβ Type II receptor degradation promotes cardiomyogenesis in embryonic stem cells Cell Stem Cell 2012, 11 (2) 242-252
4. Rose, U. Hexahydroquinolinones with calcium-modulatory effects - synthesis and pharmacologic action Arch. Pharm. (Weinheim, Ger.) 1990, 323 (5) 281-286
5. Aydin, F.; Safak, C.; Simsek, R.; Erol, K.; Ulgen, M.; Linden, A. Studies on condensed 1,4-dihydropyridine derivatives and their calcium modulatory activities Pharmazie 2006, 61 (8) 655-659
6. Takahashi, D.; Oyunzul, L.; Onoue, S.; Ito, Y.; Uchida, S.; Simsek, R.; Gunduz, M. G.; Safak, C.; Yamada, S. Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives Biol. Pharm. Bull. 2008, 31 (3) 473-479
7. Safak, C.; Simsek, R. Fused 1,4-dihydropyridines as potential calcium modulatory compounds Mini-Rev. Med. Chem. 2006, 6 (7) 747-755
8. Edraki, N.; Mehdipour, A. R.; Khoshneviszadeh, M.; Miri, R. Dihydropyridines: evaluation of their current and future pharmacological applications Drug Discovery Today 2009, 14 (21-22) 1058-1066
9. Derynck, R.; Miyazono, K. TGFβ and the TGFβ Family. In The TGFβ Family; Derynck, R.; Miyazono, K., Eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2008; pp 29-43.
10. Wharton, K.; Derynck, R. TGFbeta family signaling: novel insights in development and disease Development 2009, 136 (22) 3691-3697
11. Yingling, J. M.; Blanchard, K. L.; Sawyer, J. S. Development of TGF-beta signalling inhibitors for cancer therapy Nature Rev. Drug Discovery 2004, 3 (12) 1011-1022
12. Nagaraj, N. S.; Datta, P. K. Targeting the transforming growth factor-beta signaling pathway in human cancer Expert Opin. Investig. Drugs 2010, 19 (1) 77-91
13. Biernacka, A.; Dobaczewski, M.; Frangogiannis, N. G. TGF-beta signaling in fibrosis Growth Factors 2011, 29 (5) 196-202
14. Ko, S.; Sastry, M. N. V.; Lin, C.; Yao, C.-F. Molecular iodine-catalyzed one-pot synthesis of 4-substituted-1,4-dihydropyridine derivatives via Hantzsch reaction Tetrahedron Lett. 2005, 46, 5771-5774
15. 2+ antagonism and thromboxane A2 synthase inhibition J. Med. Chem. 1993, 36 (20) 2964-2972
16. Zolfigol, M. A.; Bagherzadehb, M.; Niknamc, K.; Shirinid, F.; Mohammadpoor-Baltorke, I.; Choghamarania, A. G.; Baghbanzadeha, M. Oxidation of 1,4-Dihydropyridines under Mild and Heterogeneous Conditions Using Solid Acids J. Iran. Chem. Soc. 2006, 3 (1) 73-80
17. Shan, R.; Howlett, S. E.; Knaus, E. E. Syntheses, Calcium Channel Agonist-Antagonist Modulation Activities, Nitric Oxide Release, and Voltage-Clamp Studies of 2-Nitrooxyethyl 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2- trifluoromethylphenyl)pyridine-5-carboxylate Enantiomers J. Med. Chem. 2002, 45 (4) 955-961
18. Gellibert, F.; de Gouville, A. C.; Woolven, J.; Mathews, N.; Nguyen, V. L.; Bertho-Ruault, C.; Patikis, A.; Grygielko, E. T.; Laping, N. J.; Huet, S. Discovery of 4-{4-[3-(Pyridin-2-yl)-1 H -pyrazol-4-yl]pyridin-2-yl}- N -(tetrahydro-2 H -pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor J. Med. Chem. 2006, 49 (7) 2210-2221
19. Gellibert, F.; Woolven, J.; Fouchet, M. H.; Mathews, N.; Goodland, H.; Lovegrove, V.; Laroze, A.; Nguyen, V. L.; Sautet, S.; Wang, R.; Janson, C.; Smith, W.; Krysa, G.; Boullay, V.; De Gouville, A. C.; Huet, S.; Hartley, D. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors J. Med. Chem. 2004, 47 (18) 4494-4506
20. Franckowiak, G.; Bechem, M.; Schramm, M.; Thomas, G. The optical isomers of the 1,4-dihydropyridine BAY K 8644 show opposite effects on Ca channels Eur. J. Pharmacol. 1985, 114 (2) 223-226
21. Inman, G. J.; Nicolas, F. J.; Callahan, J. F.; Harling, J. D.; Gaster, L. M.; Reith, A. D.; Laping, N. J.; Hill, C. S. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 Mol. Pharmacol. 2002, 62 (1) 65-74
22. Lanier, M.; Schade, D.; Willems, E.; Tsuda, M.; Spiering, S.; Kalisiak, J.; Mercola, M.; Cashman, J. R. Wnt inhibition correlates with human embryonic stem cell cardiomyogenesis: a structure-activity relationship study based on inhibitors for the Wnt response J. Med. Chem. 2012, 55 (2) 697-708
23. Willems, E.; Spiering, S.; Davidovics, H.; Lanier, M.; Xia, Z.; Dawson, M.; Cashman, J.; Mercola, M. Small-molecule inhibitors of the Wnt pathway potently promote cardiomyocytes from human embryonic stem cell-derived mesoderm Circ. Res. 2011, 109 (4) 360-364
24. Kita-Matsuo, H.; Barcova, M.; Prigozhina, N.; Salomonis, N.; Wei, K.; Jacot, J. G.; Nelson, B.; Spiering, S.; Haverslag, R.; Kim, C.; Talantova, M.; Bajpai, R.; Calzolari, D.; Terskikh, A.; McCulloch, A. D.; Price, J. H.; Conklin, B. R.; Chen, H. S.; Mercola, M. Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes PLoS One 2009, 4 (4) e5046
25. Jonk, L. J.; Itoh, S.; Heldin, C. H.; ten Dijke, P.; Kruijer, W. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer J. Biol. Chem. 1998, 273 (33) 21145-21152
26. Di Guglielmo, G. M.; Le Roy, C.; Goodfellow, A. F.; Wrana, J. L. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover Nature Cell Biol. 2003, 5 (5) 410-421
27. Bushway, P. J.; Mercola, M. High-throughput screening for modulators of stem cell differentiation Methods Enzymol. 2006, 414, 300-316
28. Takahashi, T.; Lord, B.; Schulze, P. C.; Fryer, R. M.; Sarang, S. S.; Gullans, S. R.; Lee, R. T. Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes Circulation 2003, 107 (14) 1912-1916
29. Claycomb, W. C.; Lanson, N. A., Jr.; Stallworth, B. S.; Egeland, D. B.; Delcarpio, J. B.; Bahinski, A.; Izzo, N. J., Jr. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte Proc. Natl. Acad. Sci. U.S.A. 1998, 95 (6) 2979-2984
30. Cerignoli, F.; Charlot, D.; Whittaker, R.; Ingermanson, R.; Gehalot, P.; Savtchenko, A.; Gallacher, D. J.; Towart, R.; Price, J. H.; McDonough, P. M.; Mercola, M. High throughput measurement of Ca(2+) dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. J. Pharmacol. Toxicol. Methods 2012, DOI 10.1016/j.vascn.2012.08.167.